Board summary
Key figures
39,055
Registered population
60.5% aged 18–64
21.0%
Aged 65+
ICB 19.0% · England 17.9%
3.6%
Ethnic minority (non-White)
1.4% Asian · England 9.6%
50.6%
In IMD quintile 1
ICB 31.9% · England 21.0%
~12,383
Core20 residents (est.)
Resident basis; registered basis ~22,796 · see page 3
7,293
Hypertension register
+4.31% in 3 yrs · England +5.60%
420
SMI register
18.5% of St. Helens (LAD)'s
1,309
COPD register
Reviews +3.13% in 3 yrs
Forecast to 2030
8,178
Hypertension patients, 2030
+885 on today
65.4%
QRISK ≥20% on statins, 2030
+2.12pp over 3 yrs
4.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Cardiovascular and diabetes secondary prevention lags England.
Non-frail diabetes HbA1c control (52.0% vs England's 57.4%), under-80 BP control (65.2% vs 67.8%) and QRISK ≥ 20% lipid therapy (60.9% vs 63.6%) trail.
Learning disability register fell; SMI checks trail.
Learning disability prevalence fell -7.7% (England +5.4%; +25 to +36 benchmark scenario), while SMI BP (79.1% vs 83.4%) and BMI (75.7% vs 82.1%) checks.
Heart failure and COPD reviews exceed England.
Heart failure reviews reached 80.9% (England 78.5%) after +19.8% three-year growth, alongside 80.4% annual review coverage for COPD patients (England 76.4%).
Population, age and ethnicity
Patients aged 65 and over represent 21.0% of registrations, exceeding England's 17.9%
ST HELENS CENTRAL PCN cares for 39,055 registered patients, with an older demographic shaping service planning: 21.0% (8,195 patients) are aged 65+, exceeding St. Helens (LAD) at 20.1%, the ICB at 19.0%, and England at 17.9%. Patients aged 0-17 comprise 18.5% (LAD 18.7%, ICB 19.2%, England 19.6%). Census estimates show 96.4% White ethnicity (LAD 96.5%, ICB 93.0%, England 81.1%), with a 3.6% ethnic minority share. Projected list growth to 2030 is 1.8% (LAD 1.6%, ICB 2.3%, England 2.3%), though projection methods are unverified and Census ethnicity reflects catchment residents rather than registered lists.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are St. Helens (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (St. Helens LA) | 2,208 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 77.4% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 52.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (St. Helens LA) | 1,143 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (St. Helens LA) | 24.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation spans all practices with Core20 share at 50.6% against England's 21.0%
ST HELENS CENTRAL PCN has a Core20 share of 50.6%, above St. Helens (LAD) at 38.5%, the ICB at 31.9%, and England at 21.0%. Across practices, Core20 concentration spans a 58.2 pp range, from 41.8% at Marshalls Cross Medical Centre to 100.0% at Parkfield Surgery. Core20 volume peaks at Hall Street Medical Centre (5,078) and Ormskirk House Surgery (4,447). Practice estimates sum to 22,796 registered patients versus 12,383 resident Core20 people. The PCN should adopt dual targeting by concentration and caseload volume once denominators are reconciled.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
420
SMI register
1.07% recorded prevalence
194
Learning disability register
0.50% recorded prevalence
17
Care homes, 645 beds
In the PCN catchment
11.7%
Provide unpaid care
St. Helens (LAD), Census 2021
Registers record 420 patients with severe mental illness (1.1% vs St. Helens (LAD) 1.1%, ICB 1.1%, England 1.0%) and 194 with learning disabilities (0.5% vs St. Helens (LAD) 0.6%, ICB 0.6%, England 0.6%), alongside 17 catchment care homes containing 645 beds (occupancy unmeasured).
Severe mental illness: physical health checks
On the SMI register (420 patients), annual checks trail England: blood pressure is 79.1% (England 83.4%), BMI 75.7% (England 82.1%) and alcohol status 74.7% (England 81.8%). Separate outreach is needed to close physical check gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,293
Hypertension register
+4.31%
Register growth, 3 yrs
St. Helens (LAD) +5.27% · England +5.60%
+0.83pp
BP control, under 80
≤140/90 · +4.04pp aged 80+
+885
More patients by 2030
Forecast 8,178 (20.28%)
Hypertension case-finding and control
Recorded hypertension prevalence is 18.6% (7,293 patients), close to St. Helens (LAD) (18.7%) and above the ICB (16.8%) and England (15.2%). Practice prevalence ranges from 14.2% at Marshalls Cross Medical Centre to 23.6% at Parkfield Surgery. While 86.8% of hypertensive patients had a recent blood pressure check (England 90.0%), blood pressure control under age 80 is 65.2%, trailing St. Helens (LAD) (65.9%), the ICB (66.4%) and England (67.8%). Observation periods were not supplied and rates are not age-adjusted. Lower under-80 blood pressure control than across England suggests an opportunity to prioritise systematic medication titration and recall for patients aged under 80.
Lipids and statins
For patients with QRISK ≥ 20%, 60.9% receive lipid-lowering therapy, trailing St. Helens (LAD) (62.1%), the ICB (63.2%) and England (63.6%). Adult lipid-regulating prescribing (2026) is 2,173 items per 1,000 versus 4,100 in England. This indicates an opportunity to review lipid-lowering therapy initiation for high-risk patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 69,202 | £1.90 | £1.71 | £1.86 | £131,484 |
| Cardiovascular (all), 2025 | 116,156 | £4.54 | £4.37 | £3.33 | £527,348 |
In 2026, lipid-regulating drugs cost £1.90 per item across 69,202 items, compared with £1.75 in St. Helens (LAD), £1.71 in the ICB and £1.86 in England, representing £2,768 more than at England's unit cost. This unit-cost indicator does not establish prescribing efficiency or formulary choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+5.02%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.48%
Asthma prevalence, PCN 3-yr % change
Recorded COPD prevalence is 3.4% (1,309 patients; England 1.9%), rising +7.8% over 2023 to 2025 (England +2.6%), while annual reviews reached 80.4% (England 76.4%). Asthma prevalence is 7.7% (2,850 patients; England 6.6%), but annual reviews reached 65.4% (England 65.7%), leaving an estimated 985 patients unreviewed. Furthermore, asthma prescribing for ages 5-19 is 3,277 items per 1,000 (England 1,488). The modelled shortfall of 985 unreviewed asthma patients coincides with high paediatric prescribing, indicating an area for clinical review.
Cancer register and children's immunisation
In Q1 2025/26, cancer register prevalence is 4.0% (1,577 patients; England 3.8%). In childhood immunisations, MMR dose 1 reaches 96.2% at age 5, but dose 2 drops by 11.6 pp to 84.6% (10.4 pp below the 95.0% target). The 4-in-1 booster reaches 82.7% (12.3 pp below target), and MMR1 at 24 months is 85.5% (England 88.3%). Targeted recall is required to reduce preschool booster drop-off.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of cancers with a known stage in NHS Cheshire and Merseyside ICB (7,482 of 13,490) were diagnosed at stage 1 or 2, 19.5 pp below the 75.0% national ambition by 2028 (England 55.3%). Reaching 75.0% requires about 2,640 extra early diagnoses annually across the ICB, where early staging rose +2.6 pp between 2013 and 2022. Staged coverage was 72.8% (13,490 of 18,522). Staging is not available for PCNs. In cervical screening, ST HELENS CENTRAL PCN reached 68.4% (England 66.8%, St. Helens (LAD) 69.2%), while Phoenix Medical Centre recorded 60.7% and Newholme Surgery recorded 63.4%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For Mersey and West Lancashire Teaching Hospitals NHS Trust, performance on the 62-day referral to treatment standard fell below the 85.0% standard by 7.0 pp, while NHS Cheshire and Merseyside Integrated Care Board trailed by 8.8 pp. On the 28-day faster diagnosis standard, the trust was 2.6 pp below the 75.0% target, whereas the ICB exceeded it by 2.2 pp. On the 31-day combined treatment standard, the trust was 0.5 pp below the 96.0% standard, with the ICB trailing by 0.3 pp. These waiting standards describe trust and ICB pathways rather than PCN performance.
| Pathways within standard (%) | Mersey and West Lancashire | North Cheshire and Mersey | Liverpool | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 72.39 | 80.21 | 75.47 | 77.25 | 79.32 |
| 31-day treatment (96%) | 95.46 | 98.17 | 90.51 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.96 | 83.67 | 73.26 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mersey and West Lancashire | North Cheshire and Mersey | Liverpool | England |
|---|---|---|---|---|
| MRI | 14.04 | 0.53 | 6.42 | 21.40 |
| CT | 13.08 | 2.32 | 0.71 | 9.92 |
| Echocardiography | 34.88 | 28.04 | 12.55 | 28.48 |
| Colonoscopy | 18.04 | 15.98 | 33.14 | 30.83 |
| Gastroscopy | 18.17 | 20.24 | 44.99 | 29.02 |
| All 15 DM01 tests | 21.17 | 6.34 | 11.50 | 23.14 |
| Community services activity | St. Helens residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 48,525 | 541,280 |
| Referrals | 7,815 | 97,150 |
| Patients with a contact | 12,745 | 146,240 |
Community services (residents of St. Helens), Jun 2026 (provisional). In Jun 2026 (provisional), community contacts for St. Helens borough residents aged 65 and over reached 29,090 of 48,525 total contacts, representing a 59.9% share. These community service figures describe borough resident activity rather than PCN-level delivery.
Practice variation and patient experience
Phone access varies by 45.3 pp across practices, spanning 42.6% to 87.9%
Overall QOF achievement ranges from 67.6% at Central Surgery to 95.5% at Phoenix Medical Centre against England's 92.5%. Vaccination and immunisation achievement varies across practices by 75.6 pp, from 15.6% at Ormskirk House Surgery to 91.2% at Phoenix Medical Centre (England 55.2%). Published domain points reflect points awarded rather than direct patient coverage.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Hall Street | 93 | 78.2 | 87.5% | 72.5% | 95.2% |
| Parkfield Surgery | 103 | 100.0 | 84.1% | 80.6% | 93.1% |
| Lingholme | 98 | 53.0 | 87.9% | 80.8% | 90.5% |
| Ormskirk House | 113 | 64.4 | 78.8% | 87.8% | 88.3% |
| Newholme Surgery | 92 | 59.8 | 87.2% | 67.7% | 84.5% |
| Phoenix | 114 | 43.1 | 56.8% | 86.7% | 79.2% |
| Marshalls Cross | 106 | 41.8 | 42.6% | 70.1% | 78.1% |
| Central Surgery | 109 | 42.5 | 70.8% | 51.6% | 77.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Learning disability prevalence changed -7.7% over three years (England +5.4%) while depression increased +13.2%
Over 2023 to 2025, learning disability prevalence recorded a 3-year change of -7.7% (England +5.4%, NHS Cheshire and Merseyside Integrated Care Board +3.9%, St. Helens (LAD) -0.9%) and stroke prevalence recorded -1.8% (England +2.3%, ICB +1.9%, LAD +0.9%). In contrast, heart failure reviews rose +19.8% (England +8.7%, LAD -3.8%) to 80.9% (England 78.5%), and depression prevalence increased +13.2% to 19.0% (6,062 patients aged 18+; England 14.3%). Slower register growth alongside expanding depression prevalence could reflect local coding differences, which cross-practice register audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Stroke register
Alcohol record (psychosis)
QRISK statin treatment
Asthma register
Heart failure reviews
Smoking support (SMI)
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | St. Helens (LAD) | Asset | PCN | St. Helens (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 17 (645 beds) | n/a | Schools (catchment) | 59 | n/a |
| Children's centres | 4 | 8 | Places of worship | 40 | 90 |
| Libraries | 7 | 15 | Primary schools (LA maintained) | 17 | 32 |
| Primary academies | 3 | 11 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Cardiovascular and diabetes secondary prevention review
Under-80 BP control is 65.2% (England 67.8%), QRISK ≥ 20% lipid therapy is 60.9% (England 63.6%), and non-frail diabetes HbA1c ≤ 58 mmol/mol is 52.0% (1,175 of 2,259; England 57.4%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Asthma annual review and prescribing recall
Asthma review coverage is 65.4% (England 65.7%, St. Helens (LAD) 58.2%) across 2,850 patients (985 estimated unreviewed); ages 5-19 prescribing is 3,277 items per 1,000 (England 1,488). For discussion: practices could align asthma recall with repeat inhaler prescribing reviews and offer flexible after-school clinic slots for children. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Learning disability register coding validation
Learning disability QOF prevalence is 0.5% (194 patients) versus 0.6% in St. Helens (LAD), ICB and England (range +25 to +36), changing -7.7% over 2023 to 2025 (England +5.4%). For discussion: audit learning disability clinical coding and cross-check registers against local authority social-care records where data-sharing agreements exist. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Systematic SMI physical health outreach (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Cardiovascular and diabetes secondary prevention review (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Asthma annual review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 3 · Learning disability register coding validation (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
